Given that ZNF692 was primarily expressed in T and B immune cells, proximal tubular cells, and collecting duct cells, we investigated whether ZNF692 is involved in the response to ICB therapy in ccRCC. Here, ZNF692 is linked to nonpapillary renal cell carcinoma.